title: Pharmacological reactivity of resistance vessels in a rat PCOS model - vascular effects of parallel vitamin D₃ treatment.
abstract: The aim of this study was to clarify the effects of dihydrotestosterone (DHT)-induced polycystic ovary syndrome (PCOS) on pharmacological reactivity of a resistance vessel in a rat model and the possible modulatory role of 1,25-(OH)₂-cholecalciferol (vitamin D₃). The PCOS model was induced in adolescent female Wistar rats by a 10-week DHT treatment. Norepinephrine induced contractility and acetylcholine relaxation were tested in arterioles by pressure arteriography in control as well as DHT- and DHT plus vitamin D₃-treated (DHT+D3) animals. Decreased vasoconstriction and dilatation were detected after DHT treatment. Concomitant vitamin D₃ treatment increased the contractile response and resulted in more relaxed vessels. Endothelial dilation tested with acetylcholine was lower after DHT treatment, this effect was not depend on vitamin D₃ supplementation. In conclusion, hyperandrogenic state resulted in reduced endothelium- and smooth muscle-dependent vasorelaxation and constriction with a complete loss of nitric oxide (NO)-dependent relaxation compared with controls. These alterations caused by chronic DHT treatment were partially reversed by concomitant vitamin D₃ administration.
authors.affiliation: Second Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary. saralevente@gmail.com
authors.forename: Levente
authors.initials: L
authors.lastname: Sara
authors.forename: Gyorgy L
authors.initials: GL
authors.lastname: Nadasy
authors.forename: Peter
authors.initials: P
authors.lastname: Antal
authors.forename: Anna
authors.initials: A
authors.lastname: Monori-Kiss
authors.forename: Maria
authors.initials: M
authors.lastname: Szekeres
authors.forename: Gabriella
authors.initials: G
authors.lastname: Masszi
authors.forename: Emil
authors.initials: E
authors.lastname: Monos
authors.forename: Szabolcs
authors.initials: S
authors.lastname: Varbiro
mesh_terms: D000818:Animals; D001160:Arterioles / Q000187:drug effects* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002762:Cholecalciferol / Q000008:administration & dosage / Q000627:therapeutic use*; D013196:Dihydrotestosterone; D004195:Disease Models, Animal; D004343:Drug Implants; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D007279:Injections, Subcutaneous; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000503:physiopathology; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D013848:Thigh; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D004343:Drug Implants; D013196:Dihydrotestosterone; D002762:Cholecalciferol